Deutsche Bank Ag\ Mersana Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 1,596,173 shares of MRSN stock, worth $3.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,596,173

Previous 1,576,000 1.28%

Holding current value

$3.54 Million

Previous $3.17 Million 4.77%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.23 - $2.25 $24,812 - $45,389	20,173 Added 1.28%	1,596,173 $3.02 Million
Q2 2024 Aug 14, 2024	SELL	$2.0 - $4.45 $18,526 - $41,220	-9,263 Reduced 0.58%	1,576,000 $3.17 Million
Q1 2024 May 15, 2024	BUY	$2.16 - $5.94 $963,426 - $2.65 Million	446,031 Added 39.15%	1,585,263 $7.1 Million
Q4 2023 Feb 14, 2024	BUY	$1.11 - $2.34 $1.19 Million - $2.52 Million	1,076,405 Added 1713.28%	1,139,232 $2.64 Million
Q3 2023 Nov 09, 2023	SELL	$1.06 - $3.91 $1.14 Million - $4.2 Million	-1,074,916 Reduced 94.48%	62,827 $79,000
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $30,217 - $93,695	-9,811 Reduced 0.85%	1,137,743 $3.74 Million
Q1 2023 May 15, 2023	BUY	$4.0 - $7.02 $67,400 - $118,287	16,850 Added 1.49%	1,147,554 $4.72 Million
Q4 2022 Feb 13, 2023	BUY	$5.65 - $7.86 $66,907 - $93,078	11,842 Added 1.06%	1,130,704 $6.63 Million
Q3 2022 Nov 14, 2022	SELL	$4.63 - $8.0 $27,099 - $46,824	-5,853 Reduced 0.52%	1,118,862 $7.56 Million
Q2 2022 Aug 11, 2022	SELL	$2.84 - $5.0 $87,932 - $154,810	-30,962 Reduced 2.68%	1,124,715 $5.2 Million
Q1 2022 May 13, 2022	BUY	$3.74 - $6.63 $4.03 Million - $7.15 Million	1,078,665 Added 1400.65%	1,155,677 $4.61 Million
Q4 2021 Feb 11, 2022	SELL	$5.48 - $9.86 $149,028 - $268,142	-27,195 Reduced 26.1%	77,012 $479,000
Q3 2021 Nov 04, 2021	SELL	$8.56 - $14.47 $788,538 - $1.33 Million	-92,119 Reduced 46.92%	104,207 $982,000
Q2 2021 Aug 11, 2021	SELL	$13.28 - $18.07 $306,396 - $416,911	-23,072 Reduced 10.52%	196,326 $2.67 Million
Q1 2021 May 13, 2021	SELL	$15.31 - $26.52 $111,472 - $193,092	-7,281 Reduced 3.21%	219,398 $3.55 Million
Q4 2020 Feb 16, 2021	SELL	$16.84 - $27.59 $10.8 Million - $17.6 Million	-638,448 Reduced 73.8%	226,679 $6.03 Million
Q3 2020 Nov 12, 2020	BUY	$16.2 - $25.7 $13.1 Million - $20.7 Million	806,801 Added 1383.26%	865,127 $16.1 Million
Q2 2020 Aug 13, 2020	BUY	$5.24 - $23.4 $247,013 - $1.1 Million	47,140 Added 421.42%	58,326 $1.37 Million
Q1 2020 May 14, 2020	SELL	$4.41 - $9.28 $3,201 - $6,737	-726 Reduced 6.09%	11,186 $65,000
Q4 2019 Feb 14, 2020	SELL	$1.45 - $6.73 $62,555 - $290,345	-43,142 Reduced 78.36%	11,912 $68,000
Q3 2019 Nov 14, 2019	SELL	$1.54 - $4.2 $23,793 - $64,890	-15,450 Reduced 21.91%	55,054 $86,000
Q2 2019 Aug 14, 2019	SELL	$3.84 - $6.4 $414,965 - $691,609	-108,064 Reduced 60.52%	70,504 $285,000
Q1 2019 May 15, 2019	BUY	$3.51 - $7.3 $568,297 - $1.18 Million	161,908 Added 971.84%	178,568 $938,000
Q4 2018 Feb 14, 2019	SELL	$3.45 - $9.72 $52,229 - $147,151	-15,139 Reduced 47.61%	16,660 $67,000
Q3 2018 Dec 21, 2021	BUY	$10.0 - $19.02 $66,450 - $126,387	6,645 Added 26.42%	31,799 $318,000
Q3 2018 Nov 14, 2018	SELL	$10.0 - $19.02 $57,620 - $109,593	-5,762 Reduced 18.64%	25,154 $250,000
Q2 2018 Apr 21, 2020	BUY	$14.2 - $22.68 $99,385 - $158,737	6,999 Added 29.26%	30,916 $552,000
Q2 2018 Aug 14, 2018	BUY	$14.2 - $22.68 $96,276 - $153,770	6,780 Added 39.56%	23,917 $426,000
Q1 2018 Oct 18, 2019	BUY	$13.56 - $18.48 $72,125 - $98,295	5,319 Added 45.01%	17,137 $269,000
Q1 2018 May 15, 2018	BUY	$13.56 - $18.48 $5,600 - $7,632	413 Added 3.62%	11,818 $185,000
Q4 2017 Feb 14, 2018	BUY	$14.95 - $19.9 $44,222 - $58,864	2,958 Added 35.02%	11,405 $187,000
Q3 2017 Nov 14, 2017	BUY	$14.8 - $18.06 $125,015 - $152,552	8,447	8,447 $144,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $216M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account